Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted Strategy for Extra Cranial NSMGCT in Children
NCT02104986Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- May 2014
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vinblastine, bleomycin, cisplatin, etoposide and ifosfamide in non-seminomatous germ cell tumor (NSGCT) (4 arms), sponsored by Centre Léon Bérard. Primary endpoint: Progression-free survival at 24 months. Started May 2014; status: completed.
02
Drugs
vinblastinebleomycincisplatinetoposideifosfamide
03
Conditions
non-seminomatous germ cell tumor (NSGCT)
Beyond the preview
Go deeper on NCT02104986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02104986.